Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In
  • Log Out

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
  • Log Out
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
Abstract

Adjusted mean Systemic Lupus Erythematosus Disease Activity Index-2K is a predictor of outcome in SLE.

Dominique Ibañez, Dafna D Gladman and Murray B Urowitz
The Journal of Rheumatology May 2005, 32 (5) 824-827;
Dominique Ibañez
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dafna D Gladman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Murray B Urowitz
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • References
  • PDF
  • eLetters
PreviousNext
Loading

Abstract

OBJECTIVE: To test the predictability of the adjusted mean Systemic Lupus Erythematosus Disease Activity Index-2K (AMS) for main outcomes in systemic lupus erythematosus (SLE), namely presence of damage, coronary artery disease (CAD), and avascular necrosis (AVN). METHODS: Included in this study are patients with regular followup from the University of Toronto Lupus Clinic. This was defined as a minimum of 3 visits and no absence exceeding 18 consecutive months. For each visit, AMS was evaluated. The ability of the AMS to predict each of the main outcomes was evaluated through time-dependent covariate survival analysis. Adjustments to the regression models were made to include other risk factors such as sex, age at diagnosis (AGE), SLEDAI-2K at presentation (SLEDAI), disease duration (DD), and use of corticosteroids, immunosuppressives (IM), or antimalarials (AM). RESULTS: Five hundred and seventy-five patients were included covering the period from 1970 to 2002. A total of 325 developed damage, 55 had CAD, and 68 had AVN. Presence of damage was not associated with sex, SLEDAI, or AM but was significantly associated with AMS, AGE, DD, and use of steroids or IM (all p < 0.001). CAD was not associated with SLEDAI or use of steroids or AM but with all other variables AMS (p = 0.046), sex (p = 0.009), AGE (p < 0.0001), DD (p < 0.0001), and IM (p = 0.035). Predictors of AVN were DD (p = 0.032) and IM (p < 0.0001) but not sex, AGE, use of steroids, AM, SLEDAI, or AMS. CONCLUSION: AMS is associated with the presence of damage and CAD. It is not associated with AVN.

PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 32, Issue 5
1 May 2005
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Adjusted mean Systemic Lupus Erythematosus Disease Activity Index-2K is a predictor of outcome in SLE.
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Adjusted mean Systemic Lupus Erythematosus Disease Activity Index-2K is a predictor of outcome in SLE.
Dominique Ibañez, Dafna D Gladman, Murray B Urowitz
The Journal of Rheumatology May 2005, 32 (5) 824-827;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Adjusted mean Systemic Lupus Erythematosus Disease Activity Index-2K is a predictor of outcome in SLE.
Dominique Ibañez, Dafna D Gladman, Murray B Urowitz
The Journal of Rheumatology May 2005, 32 (5) 824-827;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics
  • References
  • PDF
  • eLetters

Related Articles

Cited By...

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire